Results 51 to 60 of about 19,810 (255)

Peptide receptor radionuclide therapy

, 2015
Peptide receptor radionuclide therapy (PRRT) is an internal radiation therapy which is based on specific binding of therapeutic radiopharmaceutical to somatostatin receptor (mostly sstr2) and internalization of receptor-radiopharmaceutical complex to exert radiation damage to neuroendocrine tumour cells.
Stefańska, Agnieszka, Hubalewska-Dydejczyk, Alicja, Jabrocka-Hybel, Agata, Sowa-Staszczak, Anna   +3 more
  +5 more sources

Does PRRT with standard activities of 177Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocrine tumors [PDF]

, 2008
Twenty plantain crop fields were sampled to identify Meloidogyne spp. in Tierralta and Valencia municipalities. Ten soil and root samples per field were taken to obtain the nematodes.
Amir Sabet, James Nagarajah, Ahmet Dogan, Hans-Jürgen Biersack, Amin Sabet, Stefan Guhlke, Samer Ezziddin   +6 more
core   +2 more sources

Radiolabeled CCK/gastrin peptides for imaging and therapy of CCK2 receptor-expressing tumors [PDF]

, 2010
Cholecystokinin (CCK) receptors are overexpressed in numerous human cancers, like medullary thyroid carcinomas, small cell lung cancers and stromal ovarian cancers.
Susan Roosenburg, Peter Laverman, Floris L. van Delft, Otto C. Boerman, L Aloj, L Aloj, MP Béhé, MP Béhé, MP Béhé, TM Behr, TM Behr, TM Behr, WAP Breeman, M Jong de, S Luca De, I Dijkgraaf, J Fichna, M Foucaud, AC Fröberg, S Good, M Gotthardt, R Haubner, MR Hellmich, A Imdahl, RB Innis, AC Ivy, AS Kopin, DJ Kwekkeboom, P Laverman, P Laverman, HR Maecke, SJ Mather, Y Matsumori, F Noble, F Noble, BA Nock, JA O’Donoghue, JC Reubi, J-C Reubi, J-C Reubi, H Sankaran, JP Smith, JR Upp Jr, JJ Vanderhaeghen, E Guggenberg von, SA Wank, SA Wank   +46 more
core   +1 more source

Simplified dosimetry for kidneys and tumors in 177Lu-labeled peptide receptor radionuclide therapy

EJNMMI Physics, 2022
Purpose To evaluate if satisfactory post-therapeutic image-based dosimetry can be achieved for Lu-177-DOTATATE treatments using a reduced number of image acquisitions to improve patient comfort and reduce economical costs.
Oscar Ardenfors, Joachim N. Nilsson, Daniel Thor, Cecilia Hindorf   +3 more
doaj   +1 more source

Molecular imaging of a glucagonoma with 18F-FDG PET/CT and 68Ga-DOTATATE PET/CT imaging: A case report and review of the literature

Radiology Case Reports, 2020
A 35-year-old man presented with significant weight loss of 30 kg over the previous 6 months, with newly diagnosed diabetes. Routine laboratory tests were normal, except for markedly elevated blood glucose.
Ahmed Fathala, MD, Mohammed H. Al Qahtani, PhD, Moheieldin M. Abouzied, MD   +2 more
doaj   +1 more source

Treatment challenges in and outside a specialist network setting: Pancreatic neuroendocrine tumours [PDF]

, 2019
Pancreatic Neuroendocrine Neoplasms comprise a group of rare tumours with special biology, an often indolent behaviour and particular diagnostic and therapeutic requirements.
Almar E., Arveux P., Autelitano M., Baldi I., Bara S., Barchielli A., Benfatto L., Benhamou E., Bento M. J., Bielska-Lasota M., Blaszczyk J., Bordoni A., Botta L., Bouchardy C., Bouvier A. -M., Bouvier V., Brewster D. H., Calleja N., Candela P., Caplin M., Capocaccia R., Carulla M., Clough-Gorr K., Colonna M., Comber H., De Angelis R., de Lacerda G. F., de Munain A. L., Diaz Garcia J. M., Diba C. S., Dimitrova N., Dusek L., Engel J., Ess S. M., Falcini F., Falconi M., Ferretti S., Filiberti R. A., Fusai G. K., Fusco M., Galceran J., Gatta G., Gavin A., Gennaro V., Gentilini M., Giacomin A., Gozdz S., Grosclaude P., Guizard A. -V., Hackl M., Heidrich J., Henau K., Holleczek B., Huws D. W., Iannelli A., Johannesen T. B., Jonasson J. G., Kepska K., Knijn A., Konzelmann I., Kunkler I., Lapotre-Ledoux B., Larranaga N., Leinonen M., Luttmann S., Lykoudis P. M., Madeddu A., Magi M., Malila N., Mallone S., Mangone L., Marani E., Marcos-Gragera R., Maspero S., Maynadie M., Mazzoleni G., Michiara M., Miranda A., Molinie F., Monnereau A., Moreno-Iribas C., Mousavi M., Muffatti F., Navarro C., Nennecke A., Pannozzo F., Partelli S., Pierannunzio D., Piffer S., Pildava S., Primic-Zakelj M., Rachtan J., Rashbass J., Ricci P., Robaszkiewicz M., Rossi S., Rugge M., Salmeron D., Sanchez M. J., Santaquilani M., Sardo A. S., Schubert-Fritschle G., Schvartz C., Sekerija M., Sensi F., Serraino D., Smailyte G., Spagnoli G., Stabenow R., Stracci F., Tagliabue G., Tavilla A., Torrella-Ramos A., Trama A., Tretarre B., Troussard X., Tumino R., Usala M., Van Eycken E., Velten M., Visser O., Vitale F., Woronoff A. -S., Ziino A.   +123 more
core   +1 more source

The Integration of Positron Emission Tomography With Magnetic Resonance Imaging [PDF]

, 2008
A number of laboratories and companies are currently exploring the development of integrated imaging systems for magnetic resonance imaging (MRI) and positron emission tomography (PET).
Cherry, Simon R., Jacobs, Russell E., Louie, Angelique Y.   +2 more
core   +1 more source

Polish Experience in Peptide Receptor Radionuclide Therapy

, 2012
During the period from April 2004 to December 2010, 358 patients underwent peptide receptor radionuclide therapy (PRRT) ((90)Y-DOTATATE, (177)Lu-DOTATATE, and (90)Y/(177)Lu-DOTATATE) in Poland.The majority of patients underwent (90)Y-DOTATATE therapy (n = 177) with progression-free survival (PFS)/time to progression (TTP) of 17-44 months and overall ...
Kunikowska, Jolanta, Królicki, Leszek, Sowa-Staszczak, Anna, Hubalewska-Dydejczyk, Alicja, Pawlak, Dariusz, Mikołajczak, Renata, Handkiewicz-Junak, Daria, Szaluś, Norbert, Kamiński, Grzegorz, Cwikla, Jaroslaw, Jakuciński, Maciej, Lukiewicz, Anna, Kowalska, Aldona, Gut, Pawel   +13 more
openaire   +3 more sources

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors [PDF]

, 2017
Background Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options.
Al‐nahhas, A, Ansquer, C, Anthony, L, Azevedo, I, Baudin, E, Baum, Rp, Baum, Rp, Benson, A, Benson, Ab, Berlin, J, Berlin, J, Bodei, L, Brianzoni, E, Bushnell, D, Bushnell, D, Caplin, M, Caplin, M, Chasen, B, Chiara Grana, M, Courbon, F, DELLE FAVE, Gianfranco, Delpassand, E, Delpassand, E, El Haddad, G, Erion, Jl, Freemantle, N, Garbus, S, Giammarile, F, Grande, E, Grande, E, Grossman, A, Hendifar, A, Hendifar, A, Hobday, T, Hobday, T, Jacene, H, Krenning, E, Kulkarni, Hr, Kulke, M, Kulke, Mh, Kunz, Pl, Kvols, L, Kwekkeboom, D, Lebtahi, R, Lopera Sierra, M, Manoharan, P, Mariani, G, Metz, D, Mittra, E, Mittra, E, Mora, J, Mora, J, Morse, M, O'Dorisio, Tm, Pavel, M, Pavel, M, Reed, N, Reed, N, Rindi, G, Ruszniewski, P, Ruszniewski, P, Santoro, P, Scheidhauer, K, Schipper, M, Seregni, E, Seregni, E, Severi, S, Srirajaskanthan, R, Srirajaskanthan, R, Strosberg, J, Strosberg, J, Sundin, A, Taieb, D, Thevenet, T, Van Cutsem, E, Van Cutsem, E, Weber, M, Wolin, E, Wolin, E, Yao, J, Yao, J., Öberg, K, Öberg, K   +82 more
core   +1 more source

Expanding the Indication for Novel Theranostic 177Lu-Dotatate Peptide Receptor Radionuclide Therapy: Proof-of-Concept of PRRT in Merkel Cell Cancer

Case Reports in Oncology, 2019
The field of theranostics is a new nuclear medicine tool being utilized in the treatment of different types of cancers. It couples receptor-specific based imaging predicting and guiding response to receptor-specific based radionuclide therapies.
Pashtoon M. Kasi, Akash Sharma, Manoj K. Jain   +2 more
doaj   +1 more source